Cerebral Gigantism |
|
|
Clinical Trial: Epidemiology of Vascular Inflammation & Atherosclerosis
This study is no longer recruiting patients.
Purpose
To investigate the relationship of vascular cell phenotypes to atherosclerosis.
| Condition |
|---|
| Atherosclerosis Cardiovascular Diseases Heart Diseases Coronary Arteriosclerosis Coronary Disease Cerebral Arteriosclerosis Cerebrovascular Accident |
MedlinePlus related topics: Coronary Disease; Heart Diseases; Heart Diseases--Prevention; Stroke; Vascular Diseases
Study Type: Observational
Study Design: Natural History, Cross-Sectional
Study start: July 2004; Study completion: June 2008
BACKGROUND: Currently, the predominant hypothesis regarding atherosclerosis is that it is in major part driven by two independent pathways: hyperlipidemia (the "stimulation") and inflammation (the "response"). Although vascular cells mediate the influence of inflammation on atherosclerosis, very little is known about vascular cell epidemiology and the relationship of vascular cell phenotypes to atherosclerosis. The main hypothesis tested in this study is that variation in vascular cell biology is related to the population variation in atherosclerosis.
DESIGN NARRATIVE: The cross-sectional study will be nested within a large cohort study, the Multiethnic Study of Atherosclerosis (MESA). A partial sample of 1,000 individuals who have undergone other special laboratory analyses will be identified and new measures collected as part of their upcoming site visit. A number of novel cellular phenotypes describing the innate immune response (monocyte activation, natural killer and T cell counts), the adaptive immune response (TH1 and TH2 helper cells, and memory T cells), and vessel integrity (circulating endothelial progenitor cells) will be measured in these participants. Plasma constituents will also be measured that relate to the cellular phenotypes. The overall goal is to test the hypothesis that these novel phenotypes are associated with subclinical atherosclerosis in the coronary and carotid arteries assessed by quantification of coronary calcification (CAC) and B-mode ultrasound (CIMT), in addition to the other subclinical measures available from the MESA cohort.
Eligibility
Genders Eligible for Study: Both
Criteria
Location Information
Russell Tracy, University of Vermont
More Information
Record last reviewed: December 2004
Last Updated: January 10, 2005
Record first received: July 15, 2004
ClinicalTrials.gov Identifier: NCT00087893
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Cerebral Gigantism (National Institute of Neurological Disorders and Stroke)

Not Signed In -

